James M Brophy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1461006/publications.pdf

Version: 2024-02-01

		23567	8630
313	22,936	58	146
papers	citations	h-index	g-index
323	323	323	24195
	323	323	21173
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
2	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, The, 2000, 355, 253-259.	13.7	3,134
3	The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine, 1997, 336, 525-533.	27.0	2,690
4	Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ: British Medical Journal, 2010, 340, b5087-b5087.	2.3	859
5	A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet, The, 2004, 364, 583-591.	13.7	597
6	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	1.4	402
7	Should Meta-Analyses of Interventions Include Observational Studies in Addition to Randomized Controlled Trials? A Critical Examination of Underlying Principles. American Journal of Epidemiology, 2007, 166, 1203-1209.	3.4	383
8	Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 2006, 47, 2554-2560.	2.8	357
9	\hat{l}^2 -Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine, 2001, 134, 550.	3.9	347
10	Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ: British Medical Journal, 2017, 357, j1909.	2.3	346
11	Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. Journal of Clinical Epidemiology, 2015, 68, 950-956.	5.0	318
12	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. JAMA - Journal of the American Medical Association, 2007, 298, 2634.	7.4	303
13	Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis. American Journal of Epidemiology, 2006, 164, 881-889.	3.4	242
14	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults. Annals of Internal Medicine, 2005, 142, 481.	3.9	217
15	Association Between Timeliness of Reperfusion Therapy and Clinical Outcomes in ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2010, 303, 2148.	7.4	212
16	Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Cmaj, 2007, 177, 347-351.	2.0	178
17	Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Cmaj, 2005, 173, 167-170.	2.0	174
18	Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis. Annals of Internal Medicine, 2003, 138, 777.	3.9	167

#	Article	IF	CITATIONS
19	Oral Fluoroquinolones and the Risk of Retinal Detachment. JAMA - Journal of the American Medical Association, 2012, 307, 1414.	7.4	163
20	Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. Cmaj, 2005, 173, 40-45.	2.0	142
21	Stroke in Adults With Congenital Heart Disease. Circulation, 2015, 132, 2385-2394.	1.6	140
22	Fortnightly Review: Diagnosis and management of heart failure. BMJ: British Medical Journal, 1994, 308, 321-328.	2.3	136
23	Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine, 2010, 170, 1358.	3.8	128
24	Rationale, design, implementation, and baseline characteristics of patients in the dig trial: A large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Contemporary Clinical Trials, 1996, 17, 77-97.	1.9	127
25	A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. American Journal of Medicine, 2004, 116, 300-304.	1.5	127
26	ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International, 2006, 69, 913-919.	5.2	117
27	Placing Trials in Context Using Bayesian Analysis. JAMA - Journal of the American Medical Association, 1995, 273, 871.	7.4	116
28	End-user involvement in health technology assessment (HTA) development: A way to increase impact. International Journal of Technology Assessment in Health Care, 2005, 21, 263-267.	0.5	113
29	Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. Cmaj, 2007, 176, 1429-1434.	2.0	113
30	Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. European Heart Journal, 2008, 29, 2083-2091.	2.2	113
31	Associations between ambient air pollution and daily mortality among elderly persons in Montreal, Quebec. Science of the Total Environment, 2013, 463-464, 931-942.	8.0	113
32	Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2010, 10, 24.	1.7	106
33	Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporosis International, 2016, 27, 1709-1718.	3.1	106
34	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	1.7	105
35	Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein. Circulation, 2004, 110, 934-939.	1.6	97
36	Canadian Cardiovascular Society Position Statement onÂFamilial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	1.7	93

#	Article	IF	CITATIONS
37	Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Cmaj, 2013, 185, E115-E120.	2.0	89
38	Oral fluoroquinolone use and risk of peripheral neuropathy. Neurology, 2014, 83, 1261-1263.	1.1	89
39	Identification of an NTF2-Related Factor That Binds Ran-GTP and Regulates Nuclear Protein Export. Molecular and Cellular Biology, 1999, 19, 8616-8624.	2.3	88
40	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 305-311.	0.8	87
41	Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. Cmaj, 2015, 187, E74-E81.	2.0	86
42	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
43	Presenilin structure, function and role in Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 1-15.	3.8	83
44	Treating the right patient at the right time: Access to heart failure care. Canadian Journal of Cardiology, 2006, 22, 749-754.	1.7	82
45	Isotretinoin and Risk for Inflammatory Bowel Disease. JAMA Dermatology, 2013, 149, 216.	4.1	81
46	Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA - Journal of the American Medical Association, 1995, 273, 871-875.	7.4	80
47	Statin use and risk of epilepsy. Neurology, 2010, 75, 1496-1500.	1.1	79
48	Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation,Âand Oxidative Stress. Journal of the American College of Cardiology, 2014, 64, 1441-1448.	2.8	76
49	Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ, The, 2013, 347, f6320-f6320.	6.0	73
50	Recurrent Community-acquired Pneumonia in Patients Starting Acid-suppressing Drugs. American Journal of Medicine, 2010, 123, 47-53.	1.5	71
51	Risk of acute kidney injury associated with the use of fluoroquinolones. Cmaj, 2013, 185, E475-E482.	2.0	71
52	Clinical Utility of C-Reactive Protein Measured at Admission, Hospital Discharge, and 1 Month Later to Predict Outcome in Patients With Acute Coronary Disease. Journal of the American College of Cardiology, 2008, 51, 2339-2346.	2.8	70
53	Fluctuating Inflammatory Markers in Patients With Stable Ischemic Heart Disease. Archives of Internal Medicine, 2005, 165, 221.	3.8	69
54	Cost of Cardiac Surgery in Frail Compared With Nonfrail Older Adults. Canadian Journal of Cardiology, 2017, 33, 1020-1026.	1.7	67

#	Article	IF	CITATIONS
55	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
56	Antipsychotic Drugs and Hyperglycemia in Older Patients With Diabetes. Archives of Internal Medicine, 2009, 169, 1282.	3.8	61
57	Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. Cmaj, 2006, 174, 1563-1569.	2.0	60
58	The Early Benefits of Human Papillomavirus Vaccination on Cervical Dysplasia and Anogenital Warts. Pediatrics, 2015, 135, e1131-e1140.	2.1	58
59	The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart, 2005, 93, 189-194.	2.9	57
60	Peering at peer review revealed high degree of chance associated with funding of grant applications. Journal of Clinical Epidemiology, 2006, 59, 842-848.	5.0	57
61	Trends in the prescription of antiâ€diabetic medications in the United Kingdom: a populationâ€based analysis. Pharmacoepidemiology and Drug Safety, 2009, 18, 973-976.	1.9	57
62	Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men. Circulation, 2003, 107, 1966-1971.	1.6	56
63	The interpretation of systematic reviews with meta-analyses: an objective or subjective process?. BMC Medical Informatics and Decision Making, 2008, 8, 19.	3.0	55
64	A randomized trial of two home-based exercise programmes to improve functional walking post-stroke. Clinical Rehabilitation, 2013, 27, 659-671.	2.2	53
65	Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study. Pharmacotherapy, 2015, 35, 72-78.	2.6	53
66	Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety, 2005, 4, 1005-1015.	2.4	51
67	The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiology and Drug Safety, 2007, 16, 1-4.	1.9	51
68	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1203-1210.	6.0	50
69	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 298-304.	0.8	49
70	A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American Heart Journal, 2006, 152, 263-269.	2.7	48
71	ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging. Journal of the American College of Cardiology, 2014, 63, 698-721.	2.8	47
72	Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. Cmaj, 2016, 188, 723-730.	2.0	47

#	Article	IF	CITATIONS
73	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	3.2	47
74	Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. BMC Public Health, 2011, 11, 645.	2.9	45
75	Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporosis International, 2016, 27, 1989-1998.	3.1	45
76	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. Journal of Bone and Mineral Research, 2018, 33, 419-429.	2.8	45
77	Defining, quantifying, and characterizing adult frequent users of a suburban Canadian emergency department. Canadian Journal of Emergency Medicine, 2013, 15, 214-226.	1.1	44
78	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis International, 2014, 25, 1225-1235.	3.1	44
79	To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies. American Heart Journal, 2021, 237, 62-67.	2.7	44
80	Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiology and Drug Safety, 2007, 16, 845-849.	1.9	42
81	Time Variability of C-Reactive Protein: Implications for Clinical Risk Stratification. PLoS ONE, 2013, 8, e60759.	2.5	42
82	Long-term cost-effectiveness of transcatheter versus surgical closure of secundum atrial septal defect in adults. International Journal of Cardiology, 2014, 172, 109-114.	1.7	41
83	Does the Addition of Functional Status Indicators to Case-Mix Adjustment Indices Improve Prediction of Hospitalization, Institutionalization, and Death in the Elderly?. Medical Care, 2005, 43, 1194-1202.	2.4	39
84	The cost-effectiveness of drug-eluting stents: a systematic review. Cmaj, 2007, 176, 199-205.	2.0	38
85	Selective Serotonin Reuptake Inhibitors and the Risk of Cataracts. Ophthalmology, 2010, 117, 1251-1255.	5.2	38
86	Expression of kinin B1 receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-κB. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H227-H237.	3.2	37
87	Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. CNS Drugs, 2015, 29, 985-998.	5.9	37
88	Development of a binding assay for the B1 receptors for kinins. Immunopharmacology, 1995, 29, 141-147.	2.0	36
89	A panel study in congestive heart failure to estimate the short-term effects from personal factors and environmental conditions on oxygen saturation and pulse rate. Occupational and Environmental Medicine, 2008, 65, 659-666.	2.8	36
90	Dopamine agonist use and the risk of heart failure. Pharmacoepidemiology and Drug Safety, 2012, 21, 34-41.	1.9	36

#	Article	IF	Citations
91	Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride. Journal of Urology, 2013, 190, 1811-1814.	0.4	34
92	A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Canadian Journal of Cardiology, 2008, 24, 391-395.	1.7	33
93	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment $\hat{a} \in \text{Part 2: ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology, 2011, 27, S402-S412.}$	1.7	33
94	Oral contraceptives and the risk of gallbladder disease: a comparative safety study. Cmaj, 2011, 183, 899-904.	2.0	33
95	A systematic review and meta-analysis of surgical outcomes following mitral valve surgery in octogenarians: implications for transcatheter mitral valve interventions. EuroIntervention, 2014, 9, 1225-1234.	3.2	33
96	Risk of acute myocardial infarction with realâ€world <scp>NSAID</scp> s depends on dose and timing of exposure. Pharmacoepidemiology and Drug Safety, 2018, 27, 69-77.	1.9	32
97	Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 262-265.	2.4	32
98	Regulation of kininâ€induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta. British Journal of Pharmacology, 1995, 116, 1673-1679.	5.4	31
99	Resolution of allelic and non-allelic variants of histone H1 by cation-exchange-hydrophilic-interaction chromatography. Biomedical Applications, 2000, 744, 33-46.	1.7	30
100	Physiological and perceived health effects from daily changes in air pollution and weather among persons with heart failure: A panel study. Journal of Exposure Science and Environmental Epidemiology, 2015, 25, 187-199.	3.9	30
101	Bayesian Interpretation of the EXCEL Trial and Other Randomized Clinical Trials of Left Main Coronary Artery Revascularization. JAMA Internal Medicine, 2020, 180, 986.	5.1	30
102	Cardiovascular Risk Associated with Celecoxib. New England Journal of Medicine, 2005, 352, 2648-2650.	27.0	29
103	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology, 2011, 27, S387-S401.	1.7	29
104	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
105	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open, 2018, 8, e019638.	1.9	28
106	Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. Cmaj, 2018, 190, E648-E655.	2.0	28
107	Oral Fluoroquinolones and RiskÂofÂMitralÂand Aortic Regurgitation. Journal of the American College of Cardiology, 2019, 74, 1444-1450.	2.8	28
108	Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database. BMC Cardiovascular Disorders, 2007, 7, 38.	1.7	27

#	Article	IF	Citations
109	Heart failure risk predictions in adult patients with congenital heart disease: a systematic review. Heart, 2019, 105, 1661-1669.	2.9	26
110	Are patients suffering from stable angina receiving optimal medical treatment?. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 301-308.	0.5	25
111	Treating the right patient at the right time: Access to specialist consultation and noninvasive testing. Canadian Journal of Cardiology, 2006, 22, 819-824.	1.7	25
112	Lack of Long-Term Benefits of a 6-Month Heart Failure Disease Management Program. Journal of Cardiac Failure, 2007, 13, 287-293.	1.7	25
113	Use of Statins and Angiotensin Converting Enzyme Inhibitors (ACE-Is) and the Risk of Age-Related Macular Degeneration: Nested Case-Control Study. Current Drug Safety, 2008, 3, 24-26.	0.6	25
114	Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiology and Drug Safety, 2009, 18, 362-369.	1.9	25
115	A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. International Journal of Antimicrobial Agents, 2012, 40, 479-495.	2.5	25
116	Individual- and Regional-level determinants of Human Papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study. BMC Public Health, 2014, 14, 1047.	2.9	25
117	Associations between ambient air pollution and daily mortality in a cohort of congestive heart failure: Case-crossover and nested case-control analyses using a distributed lag nonlinear model. Environment International, 2018, 113, 313-324.	10.0	25
118	The risk of death associated with delayed coronary artery bypass surgery. BMC Health Services Research, 2006, 6, 85.	2.2	24
119	Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. International Journal of Technology Assessment in Health Care, 2005, 21, 326-333.	0.5	23
120	The Cost-Effectiveness of Stem Cell Transplantations from Unrelated Donors in Adult Patients with Acute Leukemia. Value in Health, 2007, 10, 247-255.	0.3	23
121	Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal antiâ€inflammatory drugs: a caseâ€control study. Alimentary Pharmacology and Therapeutics, 2009, 29, 1188-1192.	3.7	23
122	Antipsychotic Drugs and the Risk of Hyperglycemia in Older Adults Without Diabetes: A Population-Based Observational Study. American Journal of Geriatric Psychiatry, 2011, 19, 1026-1033.	1.2	23
123	Adjusting for Partial Verification or Workup Bias in Meta-Analyses of Diagnostic Accuracy Studies. American Journal of Epidemiology, 2012, 175, 847-853.	3.4	23
124	The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Medicine, 2010, 8, 81.	5.5	22
125	Facioscapulohumeral Muscular Dystrophy Region Gene 1 Is a Dynamic RNA-Associated and Actin-Bundling Protein. Journal of Molecular Biology, 2011, 411, 397-416.	4.2	22
126	Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial. American Journal of Medicine, 2018, 131, 1228-1233.e1.	1.5	22

#	Article	IF	Citations
127	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
128	Ranking Hospitals According to Acute Myocardial Infarction Mortality. Medical Care, 2006, 44, 664-670.	2.4	21
129	Genetic Polymorphisms and the Cardiovascular Risk of Non-Steroidal Anti-Inflammatory Drugs. American Journal of Cardiology, 2010, 105, 1740-1745.	1.6	21
130	Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiology and Drug Safety, 2011, 20, 785-796.	1.9	21
131	Coronary Revascularization in Diabetic Patients. Annals of Internal Medicine, 2014, 161, 724.	3.9	21
132	Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts. Atherosclerosis, 2015, 242, 261-267.	0.8	21
133	Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012. Osteoporosis International, 2015, 26, 2845-2852.	3.1	21
134	Risk prediction models for heart failure admissions in adults with congenital heart disease. International Journal of Cardiology, 2021, 322, 149-157.	1.7	21
135	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. International Journal of Infectious Diseases, 2021, 104, 671-676.	3.3	21
136	Contemporary Cost Analysis of Single Instillation of Mitomycin After Transurethral Resection of Bladder Tumor in a Universal Health Care System. Urology, 2010, 76, 652-656.	1.0	20
137	Antiplatelet and Anticoagulant Therapy in Patients With Gastrointestinal Bleeding. JAMA - Journal of the American Medical Association, 2011, 306, 2367-74.	7.4	20
138	The association between drospirenone and hyperkalemia: a comparative-safety study. BMC Clinical Pharmacology, 2011, 11, 23.	2.5	20
139	Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer. Frontiers in Oncology, 2012, 2, 177.	2.8	20
140	Emulating a Randomised Controlled Trial With Observational Data: An Introduction to the Target Trial Framework. Canadian Journal of Cardiology, 2021, 37, 1365-1377.	1.7	20
141	Follow-up of an intervention program for caregivers of a relative with dementia living in a long-term care setting: Are there any persistent and delayed effects?. Aging and Mental Health, 2005, 9, 461-469.	2.8	19
142	Do Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Decrease the Risk of Hospitalization Secondary to Community-Acquired Pneumonia? A Nested Case-Control Study. Pharmacotherapy, 2006, 26, 479-482.	2.6	19
143	Rehabilitating digoxinThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology European Heart Journal, 2006, 27, 127-129.	2.2	19
144	Letters to the Editor. American Journal of Gastroenterology, 2007, 102, 201-221.	0.4	19

#	Article	IF	CITATIONS
145	A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency. BMC Medicine, 2010, 8, 90.	5 . 5	19
146	Selling Safety—Lessons From Muraglitazar. JAMA - Journal of the American Medical Association, 2005, 294, 2633.	7.4	18
147	Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiology, 2007, 7, 5.	1.8	18
148	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.8	18
149	Antibiotics in Primary Prevention of Stroke in the Elderly. Stroke, 2003, 34, e163-6.	2.0	17
150	Drug treatment of stable angina pectoris and mass dissemination of therapeutic guidelines: a randomized controlled trial. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 21-31.	0.5	17
151	Numbers needed to treat (needlessly?). Lancet, The, 2005, 365, 1307-1308.	13.7	17
152	Shortness of breath at night and health status in congestive heart failure: Effects of environmental conditions and health-related and dietary factors. Environmental Research, 2009, 109, 166-174.	7.5	17
153	Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecological Endocrinology, 2013, 29, 365-369.	1.7	17
154	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
155	Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?. Journal of Thrombosis and Haemostasis, 2013, 11, 1059-1068.	3 . 8	16
156	Traditional risk factors and a Genetic Risk Score are associated with age of first acute coronary syndrome. Heart, 2014, 100, 1620-1624.	2.9	16
157	The cost-effectiveness of Maze procedures using ablation techniques at the time of mitral valve surgery. International Journal of Technology Assessment in Health Care, 2009, 25, 485-496.	0.5	15
158	Microvolt T-wave alternans as a predictor of mortality and severe arrhythmias in patients with left-ventricular dysfunction: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2009, 9, 5.	1.7	15
159	Primary Angioplasty and Thrombolysis Are Both Reasonable Options in Acute Myocardial Infarction. Annals of Internal Medicine, 2004, 141, 292.	3.9	14
160	Physicians' attitudes to the pharmacological treatment of patients with stable angina pectoris. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 41-51.	0.5	14
161	Bayesian interim statistical analysis of randomised trials. Lancet, The, 1997, 349, 1166-1168.	13.7	13
162	Effects of Radiation Therapy on Vascular Responsiveness. Journal of Cardiovascular Pharmacology, 2001, 37, 381-393.	1.9	13

#	Article	IF	Citations
163	Strategies for evaluating the assumptions of the regression discontinuity design: a case study using a human papillomavirus vaccination programme. International Journal of Epidemiology, 2017, 46, dyw195.	1.9	13
164	Increasing burden of treatment in the acute coronary syndromes: is it justified?. Lancet, The, 2003, 361, 1813-1816.	13.7	12
165	Maintaining exercise involvement: the role of learned resourcefulness in process of change use. Psychology of Sport and Exercise, 2003, 4, 237-253.	2.1	12
166	Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas, 2004, 47, 175-183.	2.4	12
167	Determinants of Survival in Older Adults With Congenital Heart Disease Newly Hospitalized for Heart Failure. Circulation: Heart Failure, 2020, 13, e006490.	3.9	12
168	A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. American Heart Journal, 2022, 247, 76-89.	2.7	12
169	Usefulness of Soluble Fas Levels for Improving Diagnostic Accuracy and Prognosis for Acute Coronary Syndromes. American Journal of Cardiology, 2010, 105, 797-803.	1.6	11
170	Door-to-Balloon Time and Mortality. New England Journal of Medicine, 2014, 370, 178-182.	27.0	11
171	Risperidone and Risk of Gynecomastia in Young Men. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 671-673.	1.3	11
172	Evaluation of propensity score used in cardiovascular research: a cross-sectional survey and guidance document. BMJ Open, 2020, 10, e036961.	1.9	11
173	The dollars and sense of drug-eluting stents. Cmaj, 2005, 172, 361-362.	2.0	10
174	Cardiovascular effects of cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine, 2008, 7, 29-36.	1.5	10
175	Impact of ECG Findings and Process-Of-Care Characteristics on the Likelihood of Not Receiving Reperfusion Therapy in Patients with ST-Elevation Myocardial Infarction: Results of a Field Evaluation. PLoS ONE, 2014, 9, e104874.	2.5	10
176	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysisâ€"reply to Pazianas and Abrahamsen. Osteoporosis International, 2014, 25, 2671-2672.	3.1	10
177	Recursive multiresolution convolutional neural networks for 3D aortic valve annulus planimetry. International Journal of Computer Assisted Radiology and Surgery, 2020, 15, 577-588.	2.8	10
178	Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial. Canadian Journal of Cardiology, 2020, 36, 1805-1814.	1.7	10
179	Primary data collection in health technology assessment. International Journal of Technology Assessment in Health Care, 2007, 23, 24-29.	0.5	9
180	A Comparison of Methods for Forecasting Emergency Department Visits for Respiratory Illness Using Telehealth Ontario Calls. Canadian Journal of Public Health, 2010, 101, 464-469.	2.3	9

#	Article	IF	Citations
181	Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2015, 31, 649-657.	1.7	9
182	Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. BMJ Open, 2022, 12, e057510.	1.9	9
183	The Saskatchewan oral contraceptive cohort study of oral contraceptive use and cardiovascular risks. Pharmacoepidemiology and Drug Safety, 1993, 2, 33-49.	1.9	8
184	Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension. American Heart Journal, 2003, 145, 918.	2.7	8
185	Medical Decision Making with Incomplete Evidenceâ€"Choosing a Platelet Glycoprotein IlbIlla Receptor Inhibitor for Percutaneous Coronary Interventions. Medical Decision Making, 2005, 25, 222-228.	2.4	8
186	The benefit of cholesterol-lowering medications after coronary revascularization: A population study. American Heart Journal, 2005, 150, 282-286.	2.7	8
187	Statin wars following coronary revascularization – Evidence-based clinical practice?. Canadian Journal of Cardiology, 2006, 22, 54-58.	1.7	8
188	Validity of electron beam computed tomography for coronary artery disease: asystematic review and meta-analysis. BMC Medicine, 2007, 5, 35.	5 . 5	8
189	Comparison of the Effect of Thiazide Diuretics and Other Antihypertensive Drugs on Central Blood Pressure: Crossâ€Sectional Analysis Among Nondiabetic Patients. Journal of Clinical Hypertension, 2015, 17, 848-854.	2.0	8
190	Multicenter trials, guidelines, and uncertainties $\hat{a} \in$ Do we know as much as we think we do?. International Journal of Cardiology, 2015, 187, 600-603.	1.7	8
191	Economic Evaluation of Exercise-Based Cardiac Rehabilitation Programs for Chronic Heart Failure Patients in Colombia. Journal of Cardiopulmonary Rehabilitation and Prevention, 2016, 36, 12-19.	2.1	8
192	Outcomes of Patients With ST-Elevation Myocardial Infarction Receiving and Not Receiving Reperfusion Therapy: The Importance of Examining All Patients. Canadian Journal of Cardiology, 2016, 32, 1325.e11-1325.e18.	1.7	8
193	Irritable Bowel Syndrome and Drospirenone-Containing Oral Contraceptives; A Comparative-Safety Study. Current Drug Safety, 2012, 7, 8-15.	0.6	7
194	Fibrinolysis or Primary PCI in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 279-281.	27.0	7
195	Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study. BMC Public Health, 2014, 14, 1029.	2.9	7
196	Statin medications and the risk of gynecomastia. Clinical Endocrinology, 2018, 89, 470-473.	2.4	7
197	Variability in High-Sensitivity Cardiac Troponin T Testing in Stable Patients With and Without Coronary Artery Disease. Canadian Journal of Cardiology, 2019, 35, 1505-1512.	1.7	7
198	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2022, 11, e024833.	3.7	7

#	Article	IF	Citations
199	Confounding in Database Pharmacoepidemiology Studies. Epidemiology, 2008, 19, 360-361.	2.7	6
200	Conflicting Evidence: What's a Clinician to Do?. Annals of Internal Medicine, 2010, 153, 413.	3.9	6
201	Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users. Annals of Internal Medicine, 2011, 155, JC4.	3.9	6
202	Analysis of Willingness to Pay for Implantable Cardioverter–Defibrillator Therapy. American Journal of Cardiology, 2011, 107, 423-427.	1.6	6
203	Statistical problems with study on milk intake and mortality and fractures. BMJ, The, 2014, 349, g6991-g6991.	6.0	6
204	Risk of readmission after heart failure hospitalization in older adults with congenital heart disease. International Journal of Cardiology, 2020, 320, 70-76.	1.7	6
205	Acute ischemic heart disease and interventional cardiology: a time for pause. BMC Medicine, 2006, 4, 25.	5.5	5
206	Adverse Outcomes Associated With Use of Proton Pump Inhibitors and Clopidogrel. JAMA - Journal of the American Medical Association, 2009, 302, 29.	7.4	5
207	Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study. International Journal of Technology Assessment in Health Care, 2009, 25, 151-160.	0.5	5
208	Therapeutic Management in Patients with Renal Failure who Experience an Acute Coronary Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 87-94.	4.5	5
209	Routine invasive management after fibrinolysis in patients with ST-elevation myocardial infarction: a systematic review of randomized clinical trials. BMC Cardiovascular Disorders, 2011, 11, 34.	1.7	5
210	Willingness To Pay To Eliminate the Risk of Restenosis Following Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 46-52.	2.2	5
211	Estimating the Risk of Cardiac Mortality After Exposure to Conducted Energy Weapons. Canadian Journal of Cardiology, 2015, 31, 1439-1446.	1.7	5
212	Mortality risk of sotalol and amiodarone for post-CABG atrial fibrillation. International Journal of Cardiology, 2016, 214, 502-507.	1.7	5
213	Sharing the Process of Diagnostic Decision Making. JAMA Internal Medicine, 2017, 177, 1245.	5.1	5
214	Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction. PLoS ONE, 2018, 13, e0201884.	2.5	5
215	Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID-19): A structured summary of a study protocol for a randomized controlled trial. Trials, 2021, 22, 115.	1.6	5
216	Comparative effectiveness and safety of highâ€dose rivaroxaban and apixaban for atrial fibrillation: A propensity scoreâ€matched cohort study. Pharmacotherapy, 2021, 41, 379-393.	2.6	5

#	Article	lF	Citations
217	Enthusiasm, reality, and cost-effectiveness analysis. Heart, 1998, 79, 9-10.	2.9	4
218	The disutility of restenosis – the impact of repeat percutaneous coronary intervention on quality of life. Canadian Journal of Cardiology, 2010, 26, e197-e200.	1.7	4
219	Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. Archives of Internal Medicine, 2012, 172, 621.	3.8	4
220	A Non-inferiority Framework for Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care, 2019, 35, 291-297.	0.5	4
221	Mortality Benefit of Alirocumab: A Bayesian Perspective. Journal of the American Heart Association, 2019, 8, e013170.	3.7	4
222	The COVID-19 Pandemic and Coronary Angiography for ST-Elevation Myocardial Infarction, Use of Mechanical Support, and Mechanical Complications in Canada: A Canadian Association of Interventional Cardiology National Survey. CJC Open, 2021, 3, 1125-1131.	1.5	4
223	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Frontiers in Pharmacology, 2021, 12, 812018.	3.5	4
224	Quality of Life after Myocardial Infarction: Canada versus the United States. New England Journal of Medicine, 1995, 332, 469-472.	27.0	3
225	Medical Decision Making in the Choice of a Thrombolytic Agent for Acute Myocardial Infarction. Medical Decision Making, 1999, 19, 411-418.	2.4	3
226	Long-term ACE-inhibitor therapy. Lancet, The, 2000, 356, 338.	13.7	3
227	COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?. Expert Opinion on Drug Safety, 2006, 5 , 1 -2.	2.4	3
228	Has thrombolysis lost its mojo?. Heart, 2007, 93, 1167-1169.	2.9	3
229	A comparison of suicide rates between older adults in Ireland and the UK: 1975–2005. Irish Journal of Medical Science, 2008, 177, 333-337.	1.5	3
230	Differences Between Conditional and Marginal Propensity Score Estimates. Journal of the American College of Cardiology, 2017, 70, 117.	2.8	3
231	Bayesian Analyses of Cardiovascular Trials—Bringing Added Value to the Table. Canadian Journal of Cardiology, 2021, 37, 1415-1427.	1.7	3
232	Key Issues in the Statistical Interpretation of Randomized Clinical Trials. Canadian Journal of Cardiology, 2021, 37, 1312-1321.	1.7	3
233	Vioxx redux – or how I learned to worry about industry-sponsored clinical trials. Indian Journal of Medical Ethics, 2016, 1, 224-226.	0.4	3
234	Determining Appropriateness of Coronary Thrombolysis in the Emergency Department. Annals of Emergency Medicine, 1998, 31, 12-18.	0.6	2

#	Article	IF	Citations
235	Thrombolytic Therapy for Myocardial Infarction. New England Journal of Medicine, 1998, 338, 545-548.	27.0	2
236	Improved Clinical Outcome after Widespread Use of Coronary-Artery Stenting in Canada. New England Journal of Medicine, 2000, 342, 1448-1449.	27.0	2
237	GRACIA: implications for clinical practice. Lancet, The, 2005, 365, 381.	13.7	2
238	Vascular events with selective COX2 inhibitors and NSAIDs: analyzing the risks. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 586-587.	3.3	2
239	Pravastatin and cancer: an unproven association. Cmaj, 2007, 176, 646-647.	2.0	2
240	Primary PCI in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2008, 358, 1751-1753.	27.0	2
241	Continuation of Statin Treatment and Mortality: A Note of Caution on Excessive Benefits. Archives of Internal Medicine, 2009, 169, 1069.	3.8	2
242	Risperidone Use and Risk for Gynecomastia in Men. Journal of Clinical Psychopharmacology, 2014, 34, 656-657.	1.4	2
243	Improving the evidence base for better comparative effectiveness research. Journal of Comparative Effectiveness Research, 2015, 4, 525-535.	1.4	2
244	Urban–rural differences in the uptake of new oral bisphosphonate formulations. Archives of Osteoporosis, 2016, 11, 11.	2.4	2
245	Cardiac Resynchronization Therapy in Heart Failure: Do Evidence-Based Guidelines Follow the Evidence?. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	2
246	Challenges in Assessing the Incidence of Atrial Fibrillation Hospitalizations. Canadian Journal of Cardiology, 2019, 35, 1291-1293.	1.7	2
247	Distorting Effect of Immortal Time Bias on the Association Between Catheter Ablation for Atrial Fibrillation and Incident Stroke: Caveat Emptor. Canadian Journal of Cardiology, 2021, 37, 377-381.	1.7	2
248	The long term prognosis in patients following thrombolysis for acute myocardial infarction: a view from a community hospital. International Journal of Cardiology, 1996, 55, 277-283.	1.7	1
249	Primary angioplasty or thrombolysis? a topical parable. BMJ: British Medical Journal, 2004, 328, 1257-1258.	2.3	1
250	The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. Annals of Internal Medicine, 2005, 143, 617.	3.9	1
251	A model combining clinical assessment and NT-proBNP level accurately predicted heart failure in ED patients with dyspnea. Annals of Internal Medicine, 2010, 152, JC1.	3.9	1
252	Retinal Detachment and Fluoroquinolonesâ€"Reply. JAMA - Journal of the American Medical Association, 2012, 308, 233.	7.4	1

#	Article	IF	CITATIONS
253	Review: Low-quality evidence fails to show that antihypertensive drugs affect outcomes in mild hypertension. Annals of Internal Medicine, 2012, 157, JC6.	3.9	1
254	Costs associated with hospital admission for heart failure in two hospitals in the city of bogota, Colombia. Value in Health, 2013, 16, A190.	0.3	1
255	Educating the Adolescent and Young Adult With Cystic Fibrosis About Their Reproductive Risks and Options: Response. Chest, 2013, 143, 580.	0.8	1
256	Longitudinal trends in sFas, a biomarker of apoptosis, after an acute coronary syndrome: Clues to the pathogenesis underlying adverse events on follow-up. International Journal of Cardiology, 2014, 173, 603-607.	1.7	1
257	Antibiotics and sudden death in adults taking renin-angiotensin system blockers. BMJ, The, 2014, 349, g6242-g6242.	6.0	1
258	Placing HPS2-THRIVE in context using Bayesian analysis. International Journal of Cardiology, 2015, 195, 203-204.	1.7	1
259	Authors' reply to Wicks. BMJ: British Medical Journal, 2017, 358, j3434.	2.3	1
260	Big Data to Assess Potential Pregnancy-Related Cardiovascular Complications of Difficult Labourâ€"Original Investigator-Driven Research Is Not Dead!. Canadian Journal of Cardiology, 2018, 34, 6-7.	1.7	1
261	Response by Labos et al to Letter Regarding Article, "Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression― Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e87-e88.	2.4	1
262	Food for Thought: A "Low-Tech―Road to Improved Primary Cardiovascular Prevention: Adherence to Dietary Guidelines. Canadian Journal of Cardiology, 2018, 34, 1551-1552.	1.7	1
263	The Reply. American Journal of Medicine, 2019, 132, e24-e25.	1.5	1
264	Revascularizing Diabetic Multivessel Coronary Artery Disease in the 2020s. Journal of the American College of Cardiology, 2020, 76, 1165-1167.	2.8	1
265	n-3 polyunsaturated fatty acids reduced morbidity and mortality in chronic heart failure. Annals of Internal Medicine, 2009, 150, JC1.	3.9	1
266	The use of cholesterol-lowering medications after coronary revascularization. Cmaj, 2003, 169, 1153-7.	2.0	1
267	Thrombolytic therapy for myocardial infarction. Annals of Emergency Medicine, 1988, 17, 760.	0.6	0
268	Placing trials in context using bayesian analysis: GUSTO revisited by Reverend Bayes. ACC Current Journal Review, 1995, 4, 72.	0.1	0
269	Bayesian Analysis and the GUSTO Trial-Reply. JAMA - Journal of the American Medical Association, 1995, 274, 874.	7.4	0
270	Bayesian interim analysis of randomised trials. Lancet, The, 1997, 349, 1911.	13.7	0

#	Article	IF	Citations
271	The EUROPA trial. Lancet, The, 2003, 362, 1936.	13.7	O
272	Misplaced pacemaker wire as a cause of mitral regurgitation. British Heart Journal, 2003, 89, 246-246.	2.1	0
273	Routine clinical variables predicted mortality in patients with heart failure and systolic dysfunction. Evidence-Based Medicine, 2004, 9, 154-154.	0.6	0
274	73 Asbestos disease: A Canadian case study. Lung Cancer, 2006, 54, S18.	2.0	0
275	Drug-eluting stents. Cmaj, 2007, 176, 1612-1613.	2.0	0
276	Vaccination against human papillomavirus. Cmaj, 2007, 177, 1525-1526.	2.0	0
277	Combined antithrombotic therapy. Cmaj, 2007, 178, 327-328.	2.0	0
278	Title is missing!. Canadian Journal of Cardiology, 2007, 23, 319.	1.7	0
279	Risk stratification following non-ST segment elevation myocardial infarction: Is the glass half-full or half-empty?. Canadian Journal of Cardiology, 2007, 23, 1080-1081.	1.7	0
280	Reply. Journal of the American College of Cardiology, 2008, 52, 1500-1501.	2.8	0
281	Resource allocation among cardiovascular specialists and trainees: A pilot survey. Canadian Journal of Cardiology, 2008, 24, 118-120.	1.7	0
282	Antipsychotic Use and Risk for Hyperglycemia in Elderly Patients With DMâ€"Reply. Archives of Internal Medicine, 2009, 169, 2162.	3.8	0
283	Routine Early Angioplasty after Fibrinolysis. New England Journal of Medicine, 2009, 361, 1507-1510.	27.0	0
284	001 Long-term outcomes of patients with ST-elevation myocardial infarction with and without reperfusion therapy: Results of a systematic province-wide field evaluation in Qu \tilde{A} ©bec. Canadian Journal of Cardiology, 2011, 27, S61.	1.7	0
285	Review: Varenicline is better than placebo or bupropion, but not clearly different from the nicotine patch, for smoking abstinence. Annals of Internal Medicine, 2011, 154, JC4.	3.9	0
286	Development of a Genetic Risk Score to Predict Adverse Outcomes After ACS. Canadian Journal of Cardiology, 2013, 29, S292.	1.7	0
287	Revascularization Techniques in Diabetics - A (Network) Meta-Analysis in Progress. Canadian Journal of Cardiology, 2013, 29, S282-S283.	1.7	0
288	Estimating the costs of cardiac rehabilitation programs in heart failure (HF) in colombia: construction based on expert consensus. Value in Health, 2013, 16, A283.	0.3	0

#	Article	IF	CITATIONS
289	Transcatheter aortic valve replacement reduced mortality more than usual care in inoperable severe aortic stenosis. Annals of Internal Medicine, 2015, 163, JC4.	3.9	O
290	Transcatheter and surgical aortic valve replacement did not differ for mortality in severe aortic stenosis. Annals of Internal Medicine, 2015, 163, JC3.	3.9	0
291	Performance of the disease risk score in a cohort study with policy-induced selection bias. Journal of Comparative Effectiveness Research, 2015, 4, 607-614.	1.4	0
292	Reply to Letter From Kroll etÂal.â€"Risk of Death With Conducted Energy Weapons. Canadian Journal of Cardiology, 2016, 32, 1261.e13.	1.7	0
293	Trends In Oral Glucocorticoid Utilization Among Older Adults With Respiratory Disease. Value in Health, 2016, 19, A120.	0.3	0
294	STEMI Treatment 2016: Is Outcome Improvement Stalling and If So, Why?. Canadian Journal of Cardiology, 2016, 32, 1193-1196.	1.7	0
295	Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality. Annals of Internal Medicine, 2017, 166, JC7.	3.9	0
296	Letter by Brophy Regarding Article, "ImPRECISION: Limitations to Interpretation of a Large Randomized Clinical Trial― Circulation, 2017, 135, e1052-e1053.	1.6	0
297	What to Do Following Fibrinolysis for ST-Elevation Myocardial Infarction. JAMA Internal Medicine, 2017, 177, 1073.	5.1	0
298	Authors' reply to Evans. BMJ: British Medical Journal, 2017, 358, j3185.	2.3	0
299	Authors' reply to commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. International Journal of Epidemiology, 2018, 47, 674-675.	1.9	0
300	Guideline: 11 professional organizations made 106 recommendations for management of high blood pressure in adults. Annals of Internal Medicine, 2018, 169, JC27.	3.9	0
301	Review: In hypertension, intensive BP goals reduce CV events; self vs office BP measures do not improve BP at 12 mo. Annals of Internal Medicine, 2018, 169, JC26.	3.9	0
302	Update on the Familial Hypercholesterolemia Canada (FH Canada) Registry. Atherosclerosis Supplements, 2018, 32, 51-52.	1.2	0
303	Sodium, Chloride, and Cardiovascular Mortality—Open Access Data Is Worth Its Salt. Canadian Journal of Cardiology, 2018, 34, 968-969.	1.7	0
304	The Dollars and Sense of Transcatheter Aortic Valve Replacement: An Example of the Benefit of Avoiding Stenoses in Health Care Services Research. Canadian Journal of Cardiology, 2020, 36, 1194-1195.	1.7	0
305	Reply to "Risk prediction models for heart failure admissions in adults with congenital heart disease: Methodological issues― International Journal of Cardiology, 2021, 333, 96.	1.7	0
306	Domperidone Increases Harmful Cardiac Events in Parkinson's Disease: A Bayesian Re-Analysis of an Observational Study. Journal of Clinical Epidemiology, 2021, 140, 93-100.	5.0	0

#	Article	IF	CITATIONS
307	The long term prognosis in patients following thrombolysis for acute myocardial infarction: a view from a community hospital. International Journal of Cardiology, 1997, 55, 277-283.	1.7	0
308	Gender Differences in Management of Myocardial Infarction in Quebec. Journal of the American College of Cardiology, 1998, 31, 308A.	2.8	0
309	Poor perception of bronchoconstriction and hyperinflation and risk of acute asthma exaerbations: A data linkage analysis. , 2016, , .		0
310	Performance of an integrated network model: Evaluation of the first 4 years. Canadian Family Physician, 2016, 62, e448-56.	0.4	0
311	Pacemaker risk following transcatheter aortic valve replacement - A Bayesian reanalysis. International Journal of Cardiology, 2022, 355, 32-36.	1.7	0
312	Diabetes and Atrial Fibrillation: Does the type of diabetes matter?. European Journal of Preventive Cardiology, 0, , .	1.8	0
313	Big data, big expectations and big judgements. Canadian Journal of Cardiology, 2022, , .	1.7	0